SIGA Investor Relations Material
Latest events
Q4 2023
SIGA
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies
Latest reports from SIGA Technologies Inc
Access all reports
Segment Data
Access more data
Revenue by
Geography
U.S.
Canada
EMEA
APAC
Other
Expenses by
Financials
SIGA Technologies Inc is a commercial-stage pharmaceutical company. The Company's lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. TPOXX is currently undergoing a Phase III clinical assessment while Siga's RTS,S/AS01 adjuvanted vaccine product candidate has been approved by WHO as part of the INDEPENDENCE clinical program to be used in case of smallpox vaccine shortage and emergencies. From a strategic alliance with Cipla Therapeutics, SIGA plans to deliver sustained innovation and access to antibacterial drugs primarily against biothreats.
Key slides for SIGA Technologies Inc
Management Presentation
SIGA Technologies Inc
Management Presentation
SIGA Technologies Inc
Latest articles
Remembering Daniel Kahneman: Transforming Psychology and Economics
Explore Daniel Kahneman's legacy in psychology and economics, highlighting his impact on decision-making and behavioral economics.
28 Mar 2024
Deere & Company: Shaping Agriculture & Construction Since 1837
Exploring Deere & Company: A global leader in agriculture & construction equipment since 1837.
28 Mar 2024
Jane Fraser: First Female Leader of a Major Wall Street Bank
Discover the journey of Jane Fraser, CEO of Citigroup and the first female leader of a major Wall Street bank.
28 Mar 2024
Ticker symbol
Country
🇺🇸 United States